NervGen Pharma Ltd. is a Vancouver, Canada–based clinical-stage biotechnology company dedicated to the development of therapeutics that promote nerve repair and regeneration. Its core focus is on addressing central nervous system injuries and neurological disorders where myelin loss or damage to neural connections leads to severe and often irreversible deficits. By targeting key molecular pathways involved in nerve healing, NervGen aims to restore function and improve quality of life for patients affected by spinal cord injury, multiple sclerosis, and other neurodegenerative conditions.
The company’s lead asset, NVG-291, is a first-in-class inhibitor of protein tyrosine phosphatase sigma (PTPσ), an enzyme implicated in the inhibition of nerve regeneration. NVG-291 is designed to neutralize scar tissue–driven barriers to axonal regrowth, thereby facilitating repair of damaged neural networks. Preclinical studies have demonstrated the compound’s ability to enhance neuronal growth and functional recovery in models of spinal cord injury, and a Phase 1b clinical trial is under way to evaluate safety, tolerability, and preliminary efficacy in human participants. In parallel, NervGen is advancing exploratory research programs targeting other forms of neurological damage, including diabetic peripheral neuropathy and Alzheimer’s disease.
Since its founding in 2016, NervGen has built a robust intellectual property portfolio covering its novel therapeutic approach and associated biomarkers. The company initially traded on the Canadian Securities Exchange before expanding its liquidity by listing on the OTC Markets under the symbol NGENF. NervGen collaborates with leading academic institutions and research hospitals across North America to conduct its preclinical and clinical studies, leveraging external expertise in neuroscience, neurology, and regenerative medicine.
NervGen’s leadership team brings together seasoned professionals from the biotechnology, pharmaceutical development, and clinical research sectors. Guided by experienced executives and supported by a scientific advisory board of world-renowned neurologists and molecular biologists, the company is positioned to translate promising laboratory findings into meaningful therapeutic advances. As it progresses through clinical milestones, NervGen aims to address significant unmet medical needs and establish new standards of care for patients with debilitating nerve injuries and neurodegenerative disorders.
AI Generated. May Contain Errors.
